South Korea and WHO to Strengthen Biosimilar Regulation in Asia-Pacific

South Korea's Ministry of Food and Drug Safety (MFDS) is partnering with the World Health Organization (WHO) to bolster regulatory capabilities for biosimilars across the Asia-Pacific region. This collaboration aims to ensure consistent and high standards for biosimilar approvals and monitoring in the area.

The MFDS's National Institute of Food and Drug Safety Evaluation will jointly organize a workshop focused on the implementation of biosimilar evaluation guidelines. The workshop, scheduled to take place in South Korea from August 24th to 26th, will bring together regulatory officials and experts from various countries.

Under the theme "Promoting Biosimilar Regulatory Harmonization," the event is designed to facilitate the exchange of knowledge and best practices. Participants will discuss strategies for aligning regulatory approaches to biosimilars, which are crucial for increasing patient access to affordable biologic medicines. The initiative underscores South Korea's commitment to global health and its role in advancing pharmaceutical regulation in the region.